Clinical progression parameters associated with SARS-CoV-2, influenza, and respiratory syncytial virus infections in a large US integrated healthcare population
PLOS Computational Biology · 2025
DOI: 10.1371/journal.pcbi.1013723 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, 2025. Verfasst von Noah T Parker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America. Hauptthemen laut MEDLINE: COVID-19, Respiratory Syncytial Virus Infections, Influenza, Human. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: US Centers for Disease Control, Center for Forecasting and Outbreak Analytics.
Abstract (Originalsprache)
Mathematical and computational models are often used to forecast respiratory infectious disease burden, including to inform healthcare capacity. We aimed to characterize pathways of clinical progression associated with SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) infections using data from patients aged 0 to >90 years in an integrated healthcare system, whose encounters were monitored across all levels of acuity spanning virtual, ambulatory, and inpatient care settings. Using parametric survival models, we estimated probabilities of progression and distributions of time to progression from each setting to all higher-acuity settings on a cascade encompassing the following classes of events or encounters: symptoms onset; diagnostic testing; telehealth or other virtual care appointment; outpatient physician office visit; urgent care presentation; emergency department presentation; hospital admission; mechanical ventilation; and death. Our analyses included data from 59,668, 22,705, and 1,668 episodes associated with positive SARS-CoV-2, influenza, and RSV tests, respectively, between 1 April 2023 and 31 March 2024. First clinical encounters occurred in inpatient settings for only 4.7%, 3.4%, and 18.7% of SARS-CoV-2, influenza, and RSV episodes, respectively, with median times (interquartile range) of 6.8 (3.6-13.2), 6.6 (3.5-12.1), and 6.4 (3.8-10.6) days from symptoms onset to admission. Overall, 7.9% of SARS-CoV-2 episodes, 5.8% of influenza episodes, and 33.8% of RSV episodes resulted in inpatient admission, ventilation, or death. Between 40.4-62.1%, 71.6-87.3%, and 47.9-58.7% of SARS-CoV-2, influenza, and RSV infections, respectively, had encounters in lower-acuity virtual care, outpatient, or urgent care settings. For all three viruses, the proportions of cases receiving care at each level of acuity increased with older age and greater numbers of comorbid conditions. Median durations of hospital stay were 4.2 (2.6, 7.3), 4.0 (2.3, 6.8), and 4.3 (2.5, 7.4) days for SARS-CoV-2, influenza, and RSV episodes resulting in admission. These estimates provide a basis for modeling real-world clinical care requirements and the progression of respiratory viral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
- School of Public Health, University of California, Berkeley, Berkeley, California, United States of America.
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, United States of America.
- Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, United States of America.
- Chan Zuckerberg Biohub, San Francisco, California, United States of America.
- Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, United States of America.
ORCID-Profile: Sara Y Tartof, Joseph A Lewnard
Förderung
- US Centers for Disease Control
- Center for Forecasting and Outbreak Analytics
Zitieren
APA
Parker, N. T., Hong, V., Davis, G. S., Pomichowski, M., Reyes, I. A., Xie, F., Mueller, N. F., Rodriguez-Barraquer, I., Tartof, S. Y., & Lewnard, J. A. (2025). Clinical progression parameters associated with SARS-CoV-2, influenza, and respiratory syncytial virus infections in a large US integrated healthcare population. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1013723
Vancouver
Parker NT, Hong V, Davis GS, Pomichowski M, Reyes IA, Xie F, et al. Clinical progression parameters associated with SARS-CoV-2, influenza, and respiratory syncytial virus infections in a large US integrated healthcare population. PLOS Computational Biology. 2025. doi:10.1371/journal.pcbi.1013723
BibTeX
@article{Parker2025,
author = {Parker, Noah T and Hong, Vennis and Davis, Gregg S and Pomichowski, Magdalena and Reyes, Iris A and Xie, Fagen and Mueller, Nicola F and Rodriguez-Barraquer, Isabel and Tartof, Sara Y and Lewnard, Joseph A},
title = {Clinical progression parameters associated with SARS-CoV-2, influenza, and respiratory syncytial virus infections in a large US integrated healthcare population},
journal = {PLOS Computational Biology},
year = {2025},
doi = {10.1371/journal.pcbi.1013723}
}
EUVIMED